LIVIVO - Search results -

Search results

Result 1 - 10 of total 63

Search options

Article ; Online: Biomarkers in veterinary cancer screening: Applications, limitations and expectations.

Henry, Carolyn J

Veterinary journal (London, England : 1997)

2010 Volume 185, Issue 1, Page(s) 10–14

Abstract: The identification of biomarkers that distinguish diseased from normal individuals is of intense interest in many health-related fields. Potential applications for biomarkers in veterinary oncology include diagnosis, staging, prognosis and monitoring ... ...

Abstract	The identification of biomarkers that distinguish diseased from normal individuals is of intense interest in many health-related fields. Potential applications for biomarkers in veterinary oncology include diagnosis, staging, prognosis and monitoring responses to therapy. By definition, effective biomarkers for cancer screening facilitate disease identification in sub-clinically affected patients and lead to subsequent improvements in clinical outcome. Although the methods and techniques of biomarker discovery and clinical application are translatable from humans to animals, veterinary medicine has lagged behind its human counterpart in several areas. Veterinarians have previously had a flawed understanding of how to use biomarker assays appropriately and have not had the positive influence on product research and development that could advance this field. The controversies, potentials biases, and considerations relative to the clinical application of biomarker assays for cancer screening are discussed in this review.
MeSH term(s)	Animals ; Biomarkers, Tumor/analysis ; Disease Progression ; Early Detection of Cancer/veterinary ; Medical Oncology/trends ; Neoplasms/diagnosis ; Neoplasms/genetics ; Neoplasms/therapy ; Neoplasms/veterinary ; Prognosis ; Veterinary Medicine/trends
Chemical Substances	Biomarkers, Tumor
Language	English
Publishing date	2010-07
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	428614-5
ISSN	1532-2971 ; 0372-5545 ; 1090-0233
ISSN (online)	1532-2971
ISSN	0372-5545 ; 1090-0233
DOI	10.1016/j.tvjl.2010.04.005
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.B 552: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Phase I evaluation of CycloSam® (Sm‐153‐DOTMP) bone seeking radiopharmaceutical in dogs with spontaneous appendicular osteosarcoma

Selting, Kim A. / Simón, Jaime / Lattimer, Jim C. / Ketring, Alan / Axiak‐Bechtel, Sandra / Frank, Keith / Wendt, Richard E. / Bryan, Jeffrey N. / Tate, Deborah / Maitz, Charles / Lunceford, Joni / Donnelly, Lindsay / Keegan, Kevin / Henry, Carolyn J.

Veterinary Radiology & Ultrasound. 2023 Sept., v. 64, no. 5 p.982-991

2023

Abstract: Sm‐DOTMP (CycloSam®) is a newly‐patented radiopharmaceutical for bone tumor treatment. DOTMP (1,4,7,10‐tetraazacyclododecane‐1,4,7,10‐tetramethylene‐phosphonate) is a macrocyclic chelating agent with superior binding properties to ¹⁵³Sm when compared ... ...

Abstract	¹⁵³Sm‐DOTMP (CycloSam®) is a newly‐patented radiopharmaceutical for bone tumor treatment. DOTMP (1,4,7,10‐tetraazacyclododecane‐1,4,7,10‐tetramethylene‐phosphonate) is a macrocyclic chelating agent with superior binding properties to ¹⁵³Sm when compared with EDTMP (Quadramet™, used for palliative treatment of bone cancer). CycloSam® was administered at 1 mCi/kg (37 MBq/kg) in a prospective pilot study to seven dogs with bone cancer resulting in no myelosuppression. Then, 13 dogs were enrolled in a prospective clinical trial study using traditional 3+3 dose escalation and starting at 1.5 mCi/kg. Baseline evaluation included hematologic and biochemical testing, diagnosis confirmation, thoracic and limb radiographs, technetium‐99 m‐HDP bone scintigraphy, and ¹⁸F‐FDG PET scan (SUVmax). Toxicity (primary endpoint) was assessed through weekly blood counts and adverse events. Dogs received 1.5 mCi/kg (n = 4), 1.75 mCi/kg (n = 6), and 2 mCi/kg (n = 3) of ¹⁵³Sm‐DOTMP. Dose‐limiting neutropenia and thrombocytopenia were seen at 2 mCi/kg. No dose‐limiting nonhematologic toxicities occurred. Efficacy (secondary endpoint) was assessed by objective lameness measurement (body‐mounted inertial sensors), owner quality‐of‐life (QoL) questionnaire, and repeat PET scan. Objective lameness measurement improved in four dogs (53%–60% decrease) was equivocal in three dogs, and worsened in four dogs (66%–115% increase); two dogs were not evaluable. Repeat ¹⁸F‐FDG PET scan results varied and change in lameness did not consistently correlate with SUVmax changes. QoL score worsened (n = 5) or was improved/stable (n = 7). Carboplatin chemotherapy (300 mg/m2 IV every 3 weeks ×4) started 4 weeks after ¹⁵³Sm‐DOTMP injection. No dog died of chemotherapy‐related complications. All dogs completed study monitoring. The recommended dose for CycloSam® in dogs is 1.75 mCi/kg, which resulted in some pain control with minimal toxicity and was safely combined with chemotherapy.
Keywords	blood ; dogs ; drug therapy ; lameness ; neutropenia ; osteosarcoma ; pain ; positron-emission tomography ; prospective studies ; quality of life ; questionnaires ; radiology ; scintigraphy ; thrombocytopenia ; toxicity ; ultrasonics
Language	English
Dates of publication	2023-09
Size	p. 982-991.
Publishing place	John Wiley & Sons, Ltd
Document type	Article ; Online
Note	JOURNAL ARTICLE
ZDB-ID	2142058-0
ISSN	1740-8261 ; 1058-8183
ISSN (online)	1740-8261
ISSN	1058-8183
DOI	10.1111/vru.13274
Database	NAL-Catalogue (AGRICOLA)

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: Phase I evaluation of CycloSam

Selting, Kim A / Simon, Jaime / Lattimer, Jim C / Ketring, Alan / Axiak-Bechtel, Sandra / Frank, Keith / Wendt, Richard E / Bryan, Jeffrey N / Tate, Deborah / Maitz, Charles / Lunceford, Joni / Donnelly, Lindsay / Keegan, Kevin / Henry, Carolyn J

Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association

2023 Volume 64, Issue 5, Page(s) 982–991

Abstract: ... ...

Abstract	153
MeSH term(s)	Animals ; Dogs ; Antineoplastic Agents/adverse effects ; Bone Neoplasms/diagnostic imaging ; Bone Neoplasms/drug therapy ; Bone Neoplasms/veterinary ; Dog Diseases/diagnostic imaging ; Dog Diseases/drug therapy ; Fluorodeoxyglucose F18 ; Lameness, Animal/diagnostic imaging ; Lameness, Animal/drug therapy ; Osteosarcoma/diagnostic imaging ; Osteosarcoma/drug therapy ; Osteosarcoma/veterinary ; Pilot Projects ; Prospective Studies ; Quality of Life ; Radioisotopes/adverse effects ; Radiopharmaceuticals/adverse effects ; Samarium/adverse effects
Chemical Substances	1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonic acid) (65F5KPT4JK) ; Antineoplastic Agents ; Fluorodeoxyglucose F18 (0Z5B2CJX4D) ; Radioisotopes ; Radiopharmaceuticals ; Samarium (42OD65L39F) ; Samarium-153 (6Q1KA41UWM)
Language	English
Publishing date	2023-07-10
Publishing country	England
Document type	Clinical Trial, Veterinary ; Journal Article
ZDB-ID	2142058-0
ISSN	1740-8261 ; 1058-8183
ISSN (online)	1740-8261
ISSN	1058-8183
DOI	10.1111/vru.13274
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article: Not lost in translation: how study of diseases in our pets can benefit them and us.

Henry, Carolyn J / Bryan, Jeffrey N

Missouri medicine

2013 Volume 110, Issue 3, Page(s) 216–219

Abstract: Practice-changing medical discovery requires preclinical and clinical assessment be carried out using appropriate disease models. There is growing awareness of companion animals with naturally-occurring disease as such models. They offer significant ... ...

Abstract	Practice-changing medical discovery requires preclinical and clinical assessment be carried out using appropriate disease models. There is growing awareness of companion animals with naturally-occurring disease as such models. They offer significant advantages over more traditional in vivo models of induced disease. This review describes current efforts to promote translation of discoveries between human and veterinary medicine in order to more rapidly and efficiently make progress in improving the health of all human and animal patients.
MeSH term(s)	Animal Diseases/genetics ; Animals ; Animals, Domestic ; Disease Models, Animal ; Genomics ; Humans ; Missouri ; Neoplasms/veterinary ; Translational Medical Research ; Zoonoses/transmission
Language	English
Publishing date	2013-07-04
Publishing country	United States
Document type	Journal Article
ZDB-ID	427362-x
ISSN	0026-6620
ISSN	0026-6620
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 182: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Biomarkers in veterinary cancer screening: Applications, limitations and expectations

Henry, Carolyn J

Veterinary journal. 2010 July, v. 185, issue 1

2010

Abstract	The identification of biomarkers that distinguish diseased from normal individuals is of intense interest in many health-related fields. Potential applications for biomarkers in veterinary oncology include diagnosis, staging, prognosis and monitoring responses to therapy. By definition, effective biomarkers for cancer screening facilitate disease identification in sub-clinically affected patients and lead to subsequent improvements in clinical outcome. Although the methods and techniques of biomarker discovery and clinical application are translatable from humans to animals, veterinary medicine has lagged behind its human counterpart in several areas. Veterinarians have previously had a flawed understanding of how to use biomarker assays appropriately and have not had the positive influence on product research and development that could advance this field. The controversies, potentials biases, and considerations relative to the clinical application of biomarker assays for cancer screening are discussed in this review.
Keywords	dog diseases ; pets ; neoplasms ; disease detection ; disease diagnosis ; biomarkers ; animal proteins ; screening ; transcriptomics ; proteomics ; laboratory techniques ; validity ; pathogenesis ; disease severity ; therapeutics ; disease course
Language	English
Dates of publication	2010-07
Size	p. 10-14.
Document type	Article
Note	In the special issue: Biomarkers in Veterinary Medicine / edited by Ali Mobasheri and J.P. Cassidy.
ZDB-ID	428614-5
ISSN	1532-2971 ; 0372-5545 ; 1090-0233
ISSN (online)	1532-2971
ISSN	0372-5545 ; 1090-0233
DOI	10.1016/j.tvjl.2010.04.005
Database	NAL-Catalogue (AGRICOLA)

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Bonn / Germany

Z 3664: Show issues

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article: Management of transitional cell carcinoma.

Henry, Carolyn J

The Veterinary clinics of North America. Small animal practice

2003 Volume 33, Issue 3, Page(s) 597–613

Abstract: Canine TCC of the bladder is a disease for which early detection and multimodality therapy are likely to produce the most favorable results. Urine screening tests are being investigated as tools to permit earlier detection. The possibility of tumor ... ...

Abstract	Canine TCC of the bladder is a disease for which early detection and multimodality therapy are likely to produce the most favorable results. Urine screening tests are being investigated as tools to permit earlier detection. The possibility of tumor seeding must be considered when obtaining urine for analysis and when performing surgery. Because these tumors tend to be very locally invasive at the time of diagnosis and are likely to metastasize, cures are unlikely. Currently, combination protocols using chemotherapy and the nonsteroidal anti-inflammatory agent piroxicam show the most promise in producing tumor responses. Surgery and radiation therapy are useful treatment modalities in select cases. Despite advances in treatment of canine TCC, median survival times reported for prospective clinical trials have never exceeded 1 year, regardless of the treatment modality. Development of accurate tests for early tumor detection could have a significant impact on the success of treatment of this tumor in canine patients.
MeSH term(s)	Animals ; Carcinoma, Transitional Cell/diagnosis ; Carcinoma, Transitional Cell/therapy ; Carcinoma, Transitional Cell/veterinary ; Combined Modality Therapy ; Dog Diseases/diagnosis ; Dog Diseases/pathology ; Dog Diseases/therapy ; Dogs ; Neoplasm Metastasis ; Neoplasm Staging ; Urinary Bladder Neoplasms/diagnosis ; Urinary Bladder Neoplasms/therapy ; Urinary Bladder Neoplasms/veterinary
Language	English
Publishing date	2003-04-28
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	757662-6
ISSN	1878-1306 ; 0195-5616
ISSN (online)	1878-1306
ISSN	0195-5616
DOI	10.1016/s0195-5616(03)00032-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Se 252: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Book: Cancer management in small animal practice

Henry, Carolyn J / Higginbotham, Mary Lynn

2010

Author's details	[edited by] Carolyn J. Henry, Mary Lynn Higginbotham
Keywords	veterinary medicine ; Veterinary oncology. ; cat diseases ; therapeutics ; neoplasms ; dog diseases
Language	English
Size	xxviii, 403 p. :, ill. (some col.) ;, 24 cm.
Publisher	Saunders/Elsevier
Publishing place	Maryland Heights, Mo
Document type	Book
ISBN	9781416031833 ; 1416031839 ; 9781437700046 ; 1437700047
Database	NAL-Catalogue (AGRICOLA)

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Book: Cancer management in small animal practice

Henry, Carolyn J / Higginbotham, Mary Lynn

2010

Author's details	[edited by] Carolyn J. Henry, Mary Lynn Higginbotham
MeSH term(s)	Neoplasms/veterinary ; Cat Diseases/therapy ; Dog Diseases/therapy
Language	English
Size	xxviii, 403 p. :, ill., port.
Publisher	Saunders/Elsevier
Publishing place	Maryland Heights, Mo
Document type	Book
ISBN	9781416031833 ; 1416031839
Database	Catalogue of the US National Library of Medicine (NLM)

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Book ; Online: Cancer management in small animal practice

Henry, Carolyn J / Higginbotham, Mary Lynn

2010

Abstract: Cancer Management in Small Animal Practice provides you with all the tools needed to diagnose, stage, and manage the many different disease entities known as "cancer." This manual is designed to provide you with easy-to-access, clinically relevant ... ...

Author's details	[edited by] Carolyn J. Henry, Mary Lynn Higginbotham
Abstract	Cancer Management in Small Animal Practice provides you with all the tools needed to diagnose, stage, and manage the many different disease entities known as "cancer." This manual is designed to provide you with easy-to-access, clinically relevant details for complete care of the small animal cancer patient, while considering the needs, concerns, and capabilities of the client. It provides quick reference sections for information not included in current oncology texts, including drug interactions and resources for participation in clinical trials. All information is well referenced and the reference section on the accompanying website includes links to the original and related articles. The latest information including diagnostic procedures, treatment modalities, and outcome predictions to help clients make the best decisions for their pets. Expert contributors, renowned for clinical, as well as academic and research expertise, offer a wide breadth and depth of expertise. Full-color format provides accurate visual depictions of specific diseases and procedures to enhance your diagnostic capabilities. Key Points highlight critical information, enabling quick, easy access. Systems approach to diagnosis and management offers logical, systematic, head-to-tail procedure for accurate diagnosis, treatment, and prognosis. Extensive discussions of supportive care limit adverse events and increase patient survival and puts emergency information at the practitioner's fingertips. Suggested readings highlight the latest information for further investigation and research. Comprehensive drug safety guidelines thoroughly discuss all information required to safely handle and administer cancer drugs. Helpful drug formularies offer available formulations, recommended dosages, toxicities, and relative costs. Chapter on how to access clinical trials provides helpful information and hope for patients and their caregivers
MeSH term(s)	Cat Diseases/therapy ; Dog Diseases/therapy ; Neoplasms/veterinary
Keywords	Veterinary oncology
Language	English
Size	Online-Ressource (1 online resource (xxviii, 403 p.)), ill. (some col.)
Publisher	Saunders/Elsevier
Publishing place	Maryland Heights, Mo
Document type	Book ; Online
Note	Includes bibliographical references and index
ISBN	1416031839 ; 1437700047 ; 1437701981 ; 9781416031833 ; 9781437700046 ; 9781437701982
Database	Library catalogue of the German National Library of Science and Technology (TIB), Hannover

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Autologous cancer cell vaccination, adoptive T‐cell transfer, and interleukin‐2 administration results in long‐term survival for companion dogs with osteosarcoma

Flesner, Brian K / Wood, Gary W / Gayheart‐Walsten, Pamela / Sonderegger, F. Lynn / Henry, Carolyn J / Tate, Deborah J / Bechtel, Sandra M / Donnelly, Lindsay L / Johnson, Gayle C / Kim, Dae Young / Wahaus, Tammie A / Bryan, Jeffrey N / Reyes, Noe

Journal of veterinary internal medicine. 2020 Sept., v. 34, no. 5

2020

Abstract: BACKGROUND: Osteosarcoma (OSA) in dogs is an aggressive bone tumor with frequent chemotherapy failure and translational relevance for human health. HYPOTHESIS/OBJECTIVES: We hypothesized that dogs with OSA could be treated safely by ex vivo activated T‐ ... ...

Abstract	BACKGROUND: Osteosarcoma (OSA) in dogs is an aggressive bone tumor with frequent chemotherapy failure and translational relevance for human health. HYPOTHESIS/OBJECTIVES: We hypothesized that dogs with OSA could be treated safely by ex vivo activated T‐cells that were generated by autologous cancer vaccination and supported by interleukin‐2 (IL‐2) treatment with survival more than twice that reported for amputation alone. ANIMALS: Osteosarcoma‐bearing dogs (n = 14) were enrolled in a single‐arm prospective trial after complete staging before amputation. Four healthy dogs also were treated in a safety study. METHODS: Autologous cancer cell vaccinations were administered intradermally and dogs underwent leukapheresis. Mononuclear cell products were stimulated ex vivo with a T‐cell‐activating agent. Activated product was transfused and 5 SC IL‐2 injections were administered q48h. Dogs were monitored for metastasis by thoracic radiography every 3 months. RESULTS: Autologous cancer cell vaccine and activated cellular therapy (ACT) products were successfully generated. Toxicity was minimal after premedicants were instituted before ACT. With premedication, all toxicities were grade I/II. Median disease‐free interval for all dogs was 213 days. One dog developed cutaneous metastasis but then experienced spontaneous complete remission. Median survival time for all dogs was 415 days. Five dogs survived >730 days. CONCLUSIONS AND CLINICAL IMPORTANCE: This immunotherapy protocol without cytotoxic chemotherapy is safe and tolerable. Compared to historical amputation reports, survival was notably prolonged in this group of patients. Additional prospective studies are warranted to elucidate active immunologic mechanisms and further improve disease response and survival.
Keywords	T-lymphocytes ; amputation ; cytotoxicity ; dogs ; drug therapy ; human health ; interleukin-2 ; metastasis ; neoplasm cells ; osteosarcoma ; radiography ; remission ; vaccination ; vaccines ; veterinary medicine
Language	English
Dates of publication	2020-09
Size	p. 2056-2067.
Publishing place	John Wiley & Sons, Inc.
Document type	Article
Note	NAL-AP-2-clean ; JOURNAL ARTICLE
ZDB-ID	92798-3
ISSN	1939-1676 ; 0891-6640
ISSN (online)	1939-1676
ISSN	0891-6640
DOI	10.1111/jvim.15852
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Cologne/Königswinter

Zs.A 4095: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito